Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes.
A treatment regimen that takes advantage of the induction of intracellular porphyrins such as protoporphyrin IX (PPIX) by exposure to exogenous 5-amino-laevulinic acid (ALA) followed by localized exposure to visible light represents a promising new approach to photodynamic therapy (PDT). Acting upon the suggestion that the effectiveness of ALA-dependent PDT may depend upon the state of cellular differentiation, we investigated the effect of terminal differentiation upon ALA-induced synthesis of and the subsequent phototoxicity attributable to PPIX in primary mouse keratinocytes. Induction of keratinocyte differentiation augmented intracellular PPIX accumulation in cells treated with ALA. These elevated PPIX levels resulted in an enhanced lethal photodynamic sensitization of differentiated cells. The differentiation-dependent increase in cellular PPIX levels resulted from several factors including: (a) increased ALA uptake, (b) enhanced PPIX production and (c) decreased PPIX export into the culture media. Simultaneously, steady-state levels of coproporphyrinogen oxidase mRNA increased but aminolaevulinic acid dehydratase mRNA levels remained unchanged. From experiments using 12-o-tetradecanoylphorbol-13-acetate, transforming growth factor beta 1 and calcimycin we demonstrated that the increase in PPIX concentration in terminally differentiating keratinocytes is calcium- and differentiation specific. Stimulation of the haem synthetic capacity is seen in primary keratinocytes, but not in PAM 212 cells that fail to undergo differentiation. Interestingly, increased PPIX formation and elevated coproporphyrinogen oxidase mRNA levels are not limited to differentiating keratinocytes; these were also elevated in the C2C12 myoblast and the PC12 adrenal cell lines upon induction of differentiation. Overall, the therapeutic implications of these results are that the effectiveness of ALA-dependent PDT depends on the differentiation status of the cell and that this may enable selective targeting of several tissue types.
Ortel
B
B
Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Boston 02114, USA.
Chen
N
N
Brissette
J
J
Dotto
G P
GP
Maytin
E
E
Hasan
T
T
D000622:Aminolevulinic Acid / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002454:Cell Differentiation; D006418:Heme / Q000096:biosynthesis; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D010778:Photochemotherapy; D000623:Porphobilinogen Synthase / Q000235:genetics; D011524:Protoporphyrins / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats
D011524:Protoporphyrins; D012333:RNA, Messenger; D006418:Heme; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX; D000623:Porphobilinogen Synthase; D002118:Calcium